Inclusion Criteria:

   - Have advanced breast cancer or another solid tumor with the presence of a
   phosphatidylinositol 3-kinase catalytic subunit alpha (PIK3CA) H1047R mutation (or
   other Sponsor and safety review committee (SRC)-approved, activating PIK3CA mutations
   other than H1047R mutation)

   - Have adequate archival tumor tissue sample available or be approved by the Sponsor for
   enrollment if no tumor sample is available.

   - Have stopped all cancer treatment and have recovered from the major side effects

   - Have adequate organ function, as measured by blood tests

   - Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG)
   scale

   - Patients must have

      - Measurable disease

      --- Patients with non-breast tumor types must have at least 1 measurable lesion

      - Non-measurable bone disease (at least 1 bone lesion in breast cancer patients
      only)

   - For patients with an estrogen receptor (ER)+ breast cancer diagnosis:

      - If female, must be postmenopausal

      - If male, must agree to use hormone suppression

   - Phase 1a:

   -- Dose escalation and backfill patients:

      - Advanced solid tumor

      - Patients may have had up to 5 prior regimens for advanced disease

   - Phase 1b:

      - Part A:

         - ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer

         - Patients may have had up to 5 prior regimens for advanced disease ---- Prior
         cyclin dependent kinase (CDK)4/6 inhibitor therapy required

      - Part B:

         - ER+/HER2- advanced breast cancer

         - Patients may have had up to 2 prior regimens for advanced disease.

      - Part C:

         - ER+/HER2- advanced breast cancer

         - Patients may have had up to 5 prior regimens for advanced disease.

         ---- Prior CDK4/6 inhibitor therapy required.

         - Have a diagnosis of diabetes mellitus Type 2

      - Part D:

         - Advanced breast cancer

         - Patients may have had up to 5 prior regimens for advanced disease.

      - Part E:

         - Advanced solid tumor

         - Patients may have had up to 3 prior regimens for advanced disease advanced
         disease

      - Part F:

         - ER+/HER2- advanced breast cancer

         - Patients may have had up to 5 prior regimens for advanced disease

            - Prior cyclin dependent kinase (CDK)4/6 inhibitor therapy required

Exclusion Criteria:

   - Medical Conditions

      - Colorectal cancer

      - Endometrial cancers with specific concurrent oncogenic alterations

      - A history of known active or suspected

         - Diabetes mellitus Type 1 or

         - Diabetes mellitus Type 2 requiring antidiabetic medication (Phase 1a and all
         parts of Phase 1b except Part C).

         - Serious concomitant systemic disorder

   - Known or suspected history of untreated or uncontrolled central nervous system (CNS)
   involvement.

   - Active uncontrolled systemic bacterial, viral, fungal, or parasitic infection, or
   other clinically significant active disease process

   - Prior exposure to phosphatidylinositol 3-kinase/protein kinase B/mammalian target of
   rapamycin (PI3K/AKT/mTOR) inhibitor(s), except in certain circumstances